

Sangamo BioSciences, Inc.

Clinical Approval Signature Page

Protocol Number: SB-728mR-1401


Protocol Title: A Phase 1/2 Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning

Amendment 2: October 10, 2014



Winson Tang, M.D.
Vice President, Clinical Research

10/15/14
Date



Dale Ando, M.D.
Vice President Therapeutic Development and CMO

10/14/14
Date